If you’ve started semaglutide (Ozempic, Wegovy) or a similar GLP-1 receptor agonist and noticed your mood shifting — feeling flatter, less interested in things you used to enjoy, or just generally “off” — you’re not imagining it, and you’re also not alone in asking whether the medication itself could be the cause.
The honest answer is that researchers are still working this out. GLP-1 receptor agonists were developed for type 2 diabetes and weight management, but GLP-1 receptors are also present in areas of the brain involved in reward and mood regulation, which is one reason scientists have started paying closer attention to psychiatric effects, both positive and negative.
What the research actually shows
Findings so far are mixed rather than conclusive. Some observational research has suggested GLP-1 drugs might be associated with a lower risk of certain depressive symptoms in some populations, possibly related to metabolic improvements or reduced inflammation. At the same time, case reports and other studies have described new-onset or worsening depression, anhedonia (a reduced ability to feel pleasure), and mood changes in some patients after starting these medications — findings that led regulators in the EU and UK to review reports of suicidal and self-injurious thoughts in GLP-1 users, even though a causal link has not been established (GLP-1 Receptor Agonists in Mood Disorders, National Institutes of Health).
In other words: a mood signal appears real enough that it’s being actively studied, but the direction and mechanism aren’t settled. It may vary by individual, dose, how quickly weight is being lost, and other factors like sleep, nutrition, and pre-existing mental health history.
Why anhedonia specifically gets reported
Some patients describe a specific pattern: not sadness exactly, but a kind of emotional flatness — food doesn’t taste as rewarding, hobbies feel less engaging, even good news doesn’t land the way it used to. One proposed explanation is that because these drugs act on brain reward pathways (the same general systems involved in cravings and appetite), dampening “food reward” signaling may, in some people, dampen reward response more broadly. This remains a hypothesis rather than a settled mechanism, and more research is needed to understand who is affected and why.
What may help — and what to do next
If you’re noticing mood changes on a GLP-1 medication, a few general, non-dosing points are worth keeping in mind:
This is not something to self-diagnose or self-manage by adjusting your dose. Only your prescriber should make changes to your medication or schedule. Mention mood symptoms at your next appointment, or sooner if they’re significant — many prescribers specifically ask about mood during GLP-1 follow-ups precisely because this is an area of active monitoring.
Basic supports that are generally protective for mood — adequate sleep, regular movement, staying connected with people, and making sure weight loss isn’t happening so fast that it’s creating additional physical stress — are reasonable things to discuss with your care team alongside any medication-specific concerns.
If you ever have thoughts of self-harm or suicide, that is an emergency, not a side-effect discussion to have later — contact your prescriber urgently, go to an emergency room, or in the US call or text 988 (the Suicide & Crisis Lifeline) right away.
This article is for general education only and is not medical advice. It cannot account for your individual health history, other medications, or specific dose. Please talk with your prescribing doctor or pharmacist about any mood changes you’re experiencing before making any decisions about your treatment.
— Gemifys
